8-K: Fortrea Announces 2023 Financial Results and Divestiture of Endpoint Clinical and Patient Access Businesses

Fortrea reported its 2023 financial results, including a net loss for the year, and announced the divestiture of its Endpoint Clinical and Fortrea Patient Access businesses to Arsenal Capital Partners.

Summary

• Fortrea reported a full-year 2023 revenue of $3,109.0 million, a slight increase from $3,096.1 million in 2022.
• The company experienced a GAAP net loss of $(3.4) million for the full year 2023, compared to a net income of $192.9 million in 2022.
• Adjusted EBITDA for the full year was $267.3 million, down from $405.1 million in the previous year.
• For the fourth quarter of 2023, revenue was $775.4 million, with a GAAP net loss of $(36.0) million.
• The book-to-bill ratio for the fourth quarter was 1.30x, exceeding the target of 1.2x.
• Fortrea has entered into an agreement to divest its Endpoint Clinical and Fortrea Patient Access businesses to Arsenal Capital Partners for $345 million, with $295 million paid at closing and $50 million upon achieving certain milestones.
• The divestiture is expected to close in the second calendar quarter of 2024.
• Fortrea's 2024 revenue guidance is between $3,140 million and $3,205 million, with adjusted EBITDA between $280 million and $320 million, excluding the impact of the planned divestiture.

Sentiment

Score: 5

Explanation: The sentiment is neutral to slightly negative due to the reported net loss and decrease in adjusted EBITDA, but the divestiture and 2024 guidance provide some positive outlook. The company is undergoing a significant strategic shift.

Positives

• The company achieved a book-to-bill ratio of 1.30x in the fourth quarter, exceeding its target.
• The divestiture of Endpoint Clinical and Fortrea Patient Access is expected to streamline Fortrea's focus on clinical development.
• The divestiture will provide Fortrea with added financial flexibility.
• The company has provided revenue and adjusted EBITDA guidance for 2024.

Negatives

• Fortrea reported a GAAP net loss of $(3.4) million for the full year 2023, a significant downturn from the previous year's net income.
• Adjusted EBITDA for the full year decreased to $267.3 million from $405.1 million in 2022.
• The company experienced a GAAP net loss of $(36.0) million in the fourth quarter of 2023.
• The company's cash and cash equivalents were $108.6 million, while gross debt was $1,624.7 million as of December 31, 2023.

Risks

• The company's financial results are subject to various risks, including macroeconomic conditions and customer defaults.
• The divestiture of Endpoint Clinical and Fortrea Patient Access may not be completed on time or at all.
• The company may not realize the full purchase price for the divestiture transaction.
• The company's 2024 financial guidance is subject to various factors, including foreign currency exchange rates.
• The company's backlog may not be indicative of future revenues.
• The company may underprice contracts or overrun cost estimates.

Future Outlook

Fortrea targets revenues between $3,140 million and $3,205 million and adjusted EBITDA between $280 million and $320 million for the full year 2024, excluding the impact of the planned divestiture. The company aims to continue delivering excellent results for customers while improving financial results in the medium and longer term.

Management Comments

• Tom Pike, chairman and CEO of Fortrea, stated that the company successfully navigated the second half of 2023, transforming a division of a division into a leader in clinical development.
• Tom Pike also mentioned that the planned divestiture of the Patient Access and Endpoint businesses strengthens the company's focus on Phase 1 to 4 Clinical Services.
• Sam Osman, president of Enabling Services at Fortrea, expressed excitement for the next chapter for Endpoint and Fortrea Patient Access, stating that they will be distinctively positioned to manage the patient journey across clinical trials and into commercialization.

Industry Context

The divestiture of the Endpoint Clinical and Patient Access businesses reflects a trend in the CRO industry towards specialization and focus on core competencies. Fortrea's move to become a pure-play CRO aligns with this trend, allowing it to concentrate on its clinical development services. The acquisition by Arsenal Capital Partners, a firm with experience in healthcare, suggests a strategic move to enhance the growth and capabilities of the divested businesses.

Comparison to Industry Standards

• Fortrea's revenue growth of approximately 0.4% year-over-year is relatively low compared to some of its peers in the CRO industry, which have seen higher growth rates.
• The significant decrease in net income and adjusted EBITDA compared to the previous year indicates potential challenges in operational efficiency or market conditions.
• Companies like IQVIA and ICON have reported stronger financial performance in recent periods, suggesting that Fortrea may need to improve its profitability and growth trajectory.
• The book-to-bill ratio of 1.30x is a positive sign, indicating strong demand for Fortrea's services, but it needs to translate into improved financial results.
• The divestiture of non-core assets is a strategy that other CROs have also pursued to streamline operations and focus on core competencies.

Stakeholder Impact

• Shareholders may be concerned about the net loss and decreased profitability, but the divestiture could be seen as a positive strategic move.
• Employees of Endpoint Clinical and Fortrea Patient Access will transition to new ownership under Arsenal Capital Partners.
• Customers of Fortrea will see a more focused CRO with a streamlined service offering.
• The divestiture may impact suppliers and creditors of the divested businesses.

Next Steps

• Fortrea will complete the divestiture of Endpoint Clinical and Fortrea Patient Access in the second quarter of 2024.
• The company will focus on growing its core clinical development business.
• Fortrea will continue to execute its plans with discipline and focus to deliver excellent results for customers and improve financial results.

Key Dates

Keywords

Fortrea, CRO, Clinical Research Organization, Financial Results, Divestiture, Endpoint Clinical, Patient Access, Arsenal Capital Partners, EBITDA, Revenue, Book-to-bill, Clinical Services, Enabling Services